Eisai & Biogen Announce U.S. Availability Of Leqembi IQLIK Subcutaneous Injection Maintenance Dose For Early Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. announced lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi IQLIK) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer’s disease (AD) in those with mild cognitive impairment (MCI) or mild dementia (collectively referred to as early AD). After 18 months of Leqembi intravenous (IV) treatment at 10 mg/kg every two weeks, those in treatment may either continue IV infusions at 10 mg/kg once every four weeks or start the new weekly 360 mg subcutaneous injection using the Leqembi IQLIK autoinjector.

Eisai and . . .